Functional Genetic Variation in the Basal Promoter of the Organic Cation/Carnitine Transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5)

The organic cation/ergothioneine transporter OCTN1 (SLC22A4) and the high-affinity carnitine transporter OCTN2 (SLC22A5), play an important role in the disposition of xenobiotics and endogenous compounds. Here, we analyzed the sequence of the proximal promoter regions of OCTN1 and OCTN2 in four ethnic groups and determined the effects of the identified genetic variants on transcriptional activities and mRNA expression. Six variants were found in the proximal promoter of OCTN1, one of which showed high allele frequency ranging from 13 to 34% in samples from individuals with ancestries in Africa, Europe, China, and Mexico. OCTN1 haplotypes had similar activities as the reference in luciferase reporter assays. For OCTN2, three of the seven variants identified in the proximal promoter showed allele frequencies greater than 29.5% in all populations, with the exception of -207C>G (rs2631367) that was monomorphic in Asian Americans. OCTN2 haplotypes containing -207G, present in all populations, were associated with a gain of function in luciferase reporter assays. Consistent with reporter assays, OCTN2 mRNA expression levels in lymphoblastoid cell lines (LCLs) from gene expression analysis were greater in samples carrying a marker for -207G. This SNP seems to contribute to racial differences in OCTN2 mRNA expression levels in LCLs. Our study with healthy subjects (n = 16) homozygous for either -207C or -207G, showed no appreciable effect of this SNP on carnitine disposition. However, there were significant effects of gender on carnitine plasma levels (p < 0.01). Further in vivo studies of OCTN2 promoter variants on carnitine disposition and variation in drug response are warranted.

[1]  K. Giacomini,et al.  Genetic Variation in Drug Transporters in Ethnic Populations , 2008, Clinical pharmacology and therapeutics.

[2]  W. Sadee,et al.  Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. , 2008, Blood.

[3]  O. Ogawa,et al.  Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney , 2008, Journal of Human Genetics.

[4]  P. Watkins,et al.  Association of Breast Cancer Resistance Protein/ABCG2 Phenotypes and Novel Promoter and Intron 1 Single Nucleotide Polymorphisms , 2008, Drug Metabolism and Disposition.

[5]  E. Burchard,et al.  Effects of Genetic Variation in the Novel Organic Cation Transporter, OCTN1, on the Renal Clearance of Gabapentin , 2008, Clinical pharmacology and therapeutics.

[6]  K. Giacomini,et al.  Effect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin Pharmacokinetics , 2008, Clinical pharmacology and therapeutics.

[7]  Conrad C. Huang,et al.  Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). , 2007, Pharmacogenetics and genomics.

[8]  Z. Tulassay,et al.  Plasma carnitine ester profiles in Crohn's disease patients characterized for SLC22A4 C1672T and SLC22A5 G-207C genotypes , 2007, British Journal of Nutrition.

[9]  S. Vavricka,et al.  Regional Distribution of Solute Carrier mRNA Expression Along the Human Intestinal Tract , 2007, Drug Metabolism and Disposition.

[10]  K. Miyazawa,et al.  Mechanism of the Regulation of Organic Cation/Carnitine Transporter 1 (SLC22A4) by Rheumatoid Arthritis-Associated Transcriptional Factor RUNX1 and Inflammatory Cytokines , 2007, Drug Metabolism and Disposition.

[11]  R B Altman,et al.  The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response , 2007, Clinical pharmacology and therapeutics.

[12]  Judy H. Cho,et al.  Refined genomic localization and ethnic differences observed for the IBD5 association with Crohn's disease , 2007, European Journal of Human Genetics.

[13]  E. Burchard,et al.  Functional Genetic Diversity in the High-Affinity Carnitine Transporter OCTN2 (SLC22A5) , 2006, Molecular Pharmacology.

[14]  S. Higuchi,et al.  Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy , 2006, Expert opinion on drug metabolism & toxicology.

[15]  J. Verweij,et al.  Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. , 2006, The oncologist.

[16]  D. Rosskopf,et al.  Uptake of Cardiovascular Drugs Into the Human Heart: Expression, Regulation, and Function of the Carnitine Transporter OCTN2 (SLC22A5) , 2006, Circulation.

[17]  Michel Eichelbaum,et al.  Pharmacogenomics and individualized drug therapy. , 2006, Annual review of medicine.

[18]  J. Castle,et al.  Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[19]  R. Myers,et al.  Comprehensive analysis of transcriptional promoter structure and function in 1% of the human genome. , 2005, Genome research.

[20]  M. Nishimura,et al.  Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. , 2005, Biological & pharmaceutical bulletin.

[21]  Bill Newman,et al.  Functional variants of OCTN cation transporter genes are associated with Crohn disease , 2004, Nature Genetics.

[22]  H. Koepsell,et al.  The SLC22 drug transporter family , 2004, Pflügers Archiv.

[23]  Yusuke Nakamura,et al.  An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis , 2003, Nature Genetics.

[24]  Peter Donnelly,et al.  A comparison of bayesian methods for haplotype reconstruction from population genotype data. , 2003, American journal of human genetics.

[25]  Conrad C. Huang,et al.  Natural variation in human membrane transporter genes reveals evolutionary and functional constraints , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  I. Tein Carnitine transport: Pathophysiology and metabolism of known molecular defects , 2003, Journal of Inherited Metabolic Disease.

[27]  G. Mitchell,et al.  Carnitine transport by organic cation transporters and systemic carnitine deficiency. , 2001, Molecular genetics and metabolism.

[28]  J. Nezu,et al.  Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. , 2001, Molecular pharmacology.

[29]  V. Ganapathy,et al.  β-Lactam Antibiotics as Substrates for OCTN2, an Organic Cation/Carnitine Transporter* , 2000, The Journal of Biological Chemistry.

[30]  Y. Matsuzawa,et al.  Characteristics of cardiac hypertrophy in the juvenile visceral steatosis mouse with systemic carnitine deficiency. , 1998, Journal of molecular and cellular cardiology.

[31]  Y. Kato,et al.  Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart. , 2008, Drug metabolism and pharmacokinetics.

[32]  H. Hasegawa,et al.  Role of Na+/L-carnitine transporter (OCTN2) in renal handling of pivaloylcarnitine and valproylcarnitine formed during pivalic acid-containing prodrugs and valproic acid treatment. , 2008, Drug metabolism and pharmacokinetics.

[33]  Rui Gao,et al.  Pharmacogenetics of membrane transporters: a review of current approaches. , 2008, Methods in molecular biology.

[34]  M. Nishimura,et al.  Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. , 2005, Drug metabolism and pharmacokinetics.

[35]  J. Nezu,et al.  Molecular and Physiological Evidence for Multifunctionality of Carnitine / Organic Cation Transporter OCTN 2 , 2001 .